AVTX
NASDAQ HealthcareAvalo Therapeutics, Inc. - Common Stock
Biotechnology
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
�� 市场数据
| 价格 | $14.43 |
|---|---|
| 成交量 | 829,693 |
| 市值 | 328.84M |
| 贝塔系数 | 0.940 |
| RSI（14日） | 52.6 |
| 200日均线 | $13.79 |
| 50日均线 | $15.32 |
| 52周最高 | $20.72 |
| 52周最低 | $3.39 |
| Forward P/E | -4.76 |
| Price / Book | 3.22 |
🎯 投资策略评分
AVTX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (74/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🐋 Institutional Whale (8/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 AVTX in your text
粘贴任何文章、记录或帖子 — 工具将提取 AVTX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.